Research programme: anaplastic lymphoma kinase inhibitors - NovartisAlternative Names: NPM-ALK inhibitor; NVP-TAE684; TAE 684
Latest Information Update: 20 Jul 2010
At a glance
- Originator Novartis
- Developer Novartis; Scripps Institutions of Medicine and Science
- Class Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Lymphoma
Most Recent Events
- 19 Jul 2007 Preclinical trials in Lymphoma in USA (unspecified route)